BIO 2010: German Molecular Diagnostics Segment Posting Double-Digit Growth

Berlin/Chicago (ots) - Molecular diagnostics has quickly become
one of the most important biotechnology segments in Germany. With an
estimated 10 percent share of the EUR 2 billion German diagnostics
market, the segment enjoys a compound annual growth rate of around 12
percent. This growth is driven by industry trends toward personalized
medicine that are correspondingly increasing the market for molecular
diagnostics. Germany Trade & Invest will have representatives at this
year's BIO International Convention in Chicago from May 3 - 6, 2010
to share the latest business opportunities in Germany's biotechnology
industry.

There are more companies operating in the biotech and biomedical
sectors in Germany than in any other country in Europe. Revenue in
this industry has grown over 40 percent between 2005 and 2009 and
promises to expand in the coming years. Dedicated biotechnology
companies annually invest nearly EUR 1 billion in research and
development, securing the industry's innovation potential for the
coming years.

The integration of biotechnology clusters further increases the
country's attractiveness as a business location. Research institutes
and companies large and small can utilize the cluster structure to
share ideas, innovate with partners and quickly bring new products to
market. Giving a further boost to Germany's reputation as a high-tech
business location, top executives in American companies recently
selected Germany as the number one location in Europe. In a survey
conducted by the American Chamber of Commerce in Germany (AmCham
Germany), they cited Germany's handling of the economic crisis and
stable domestic demand as crucial factors. 80 percent of those
surveyed even named Germany as their future focal point for
investments in Europe. Germany Trade & Invest will be showcasing the
latest developments in Germany's biotechnology industry at Booth 4722
at this year's BIO International Convention. In addition, the
organization will be hosting a session on opportunities in Germany
under the moniker "Beyond Classical Diagnostics: Breakthroughs in
Molecular Diagnostics and Biomarkers from Germany." Speakers will
include Michael Lutz, CEO of Life Codexx, a DNA sequencing company
that develops clinically validated next generation molecular
diagnostics, as well as Hajo Schiewe, Ph.D., Manager Business
Development for Metanomics Health, a metabolite profiling company in
the area of plant biotechnology. Both will speak about opportunities
in their segments in Germany.

Germany Trade & Invest is the foreign trade and inward investment
promotion agency of the Federal Republic of Germany. The organization
advises foreign companies looking to expand their business activities
to the German market. It provides information on foreign trade to
German companies that seek to enter foreign markets.

Originaltext: Germany Trade and Invest
digital press kits: http://www.presseportal.de/pm/74441
press kits via RSS: http://www.presseportal.de/rss/pm_74441.rss2

Pressekontakt:
Germany Trade & Invest
Eva Henkel
Email: eva.henkel@gtai.com
T: +49(0)30 200099-173
F: +49(0)30 200099-111